Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.

Pharmacogenomics - 1 Apr 2020

Űrgeová Anna, Javorský Martin, Klimčáková Lucia, Židzik Jozef, Šalagovič Ján, Hubáček Jaroslav A, Doubravová Pavlina, Gotthardová Ivana, Kvapil Milan, Pelikánová Terezie, Tkáč Ivan, Yaluri Alena Stančáková

Abstract excerpt

Aim: We examined associations of eight SNPs in/near seven candidate genes with glycemic response to 6 month treatment with DPP4 inhibitors. Patients & methods: 206 patients with type 2 diabetes (116 men and 90 women) were treated with sitagliptin or vildagliptin (both 100 mg/day) in combination with metformin or metformin/sulphonylurea over 6 months, and the reduction in glycated hemoglobin (HbA1c) was measured....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Treatment and Management

Share to Metformin

Share to Pancreatic function and diabetes

Share to Peptidase Inhibition and Analysis

Source

Identifiers

PMID: 32308134
DOI: 10.2217/pgs-2019-0147

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.PMID 32308134Read ↗

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.Semantic proximity Read ↗

A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins.Semantic proximity Read ↗

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Semantic proximity Read ↗

Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity Read ↗

Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors.Semantic proximity Read ↗

Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.Semantic proximity Read ↗

GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.Semantic proximity Read ↗

KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors.Semantic proximity Read ↗

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.Semantic proximity Read ↗

Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.